DSFIR.AS DSM-Firmenich EURONEXT pre-market 11 Feb 2026: earnings focus on ANH sale

We start pre-market on 11 Feb 2026 with DSM-Firmenich (DSFIR.AS) trading at €66.82 and an earnings release due on 12 Feb 2026. DSFIR.AS stock will be watched closely after the announced sale of the Animal Nutrition & Health unit for €2.20 billion and a new €0.50 billion buyback plan. Investors must weigh the near-term non-cash impairment and cash proceeds against a stable dividend policy of €2.50 per share. This earnings spotlight explains the likely read-throughs for revenue, margins, and shareholder returns ahead of tomorrow’s report.

DSFIR.AS stock: earnings preview and key dates

Earnings release timing is the main near-term event; DSM-Firmenich reports 2025 results on 12 Feb 2026. The market opened pre-market with price €66.82, day low €66.12, day high €71.70, and volume 1,477,871 shares.

We expect management commentary to focus on the ANH divestment, share buyback plan of €0.50 billion, and guidance for 2026. These items will shape consensus revisions and short-term trading ranges.

Recent catalyst: ANH sale, impairments and cash impact

DSM-Firmenich agreed to sell the ANH business to CVC for €2.20 billion enterprise value, retaining a 20% stake and an earnout up to €0.50 billion. The company expects to receive around €1.20 billion in cash after closing and will record a €1.90 billion non-cash impairment in 2025.

The divestment and prior Novonesis sale lift strategic clarity toward a focused consumer nutrition, health and beauty group and enable the planned buyback and dividend policy updates.

Financials, valuation and Meyka grade

Key ratios show mixed signals: EPS €2.72, PE 25.92, price/book 0.87, and dividend per share €2.50 (yield 3.55%). The company’s 50-day average price is €67.76 and 200-day average is €79.55.

Meyka AI rates DSFIR.AS with a score out of 100: 67.69 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors.

Technicals and trading snapshot

Technically, momentum is soft: RSI 42.58, MACD histogram -0.04, and ADX 21.49. Price sits below the 200-day average, with Bollinger upper band €69.84 and lower band €67.18.

Trading volume is above average (relVolume 1.55), so expect higher intraday sensitivity around the earnings print and ANH-related commentary.

Analyst view, price targets and scenario planning

Sell-side consensus is thin publicly, but our scenario view frames three price targets: conservative €60.00 (-10.21%), base €75.00 (+12.24%), and upside €95.00 (+42.17%). Each target assumes different outcomes on separation costs, recurring margins, and the successful redeployment of cash.

Catalysts that could push the stock toward the upside include clearer post-divestment margins, accelerated buybacks, or higher dividend guidance.

Earnings watch: what to look for in the report

Watch revenue mix and margin commentary after the ANH separation, plus cash flow and one-off items. Expect management to detail timing for the share repurchase and cash tax, transaction and separation costs of about €0.20 billion in 2026.

We will also monitor any update to the ‘stable to preferably rising’ dividend policy and the long-term vitamins supply agreement tied to the Essential Products Company.

Final Thoughts

Key takeaways for DSFIR.AS stock ahead of the 12 Feb 2026 earnings release: the ANH deal is the primary driver for numbers and sentiment, with €2.20 billion enterprise value and expected cash proceeds near €1.20 billion. Financially the company posts EPS €2.72 and a PE of 25.92, while the dividend remains €2.50 per share. Meyka AI’s forecast model projects a monthly level near €72.06, implying an upside of 7.85% from the current €66.82, but the yearly model at €38.62 implies downside risk if structural headwinds persist. We view the next 24 hours as a volatility window: positive separation details or improved guidance support the base €75.00 case, while larger-than-expected separation costs or weaker organic trends point toward the conservative €60.00 case. Forecasts are model-based projections and not guarantees, and we recommend monitoring management comments and cash deployment updates on the earnings call. For a quick company profile see DSM-Firmenich on Meyka: DSM-Firmenich on Meyka. Sources: Nasdaq and Investing.com. Meyka AI is an AI-powered market analysis platform

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.